Experiencia con ixabepilona como tratamiento de primera línea para el cáncer de mama metastásico en América Latina

Adriana Tomadoni; Andrés F. Cardona; Juan Lacava; Manuel Magallanes

doi:10.56969/oc.v17i4.125

Autores/as

Adriana Tomadoni Servicio de Oncología, Hospital Nacional Prof. Alejandro Posadas, Buenos Aires
Andrés F. Cardona Grupo Oncología Clínica y Traslacional, Fundación Santa Fe de Bogotá
Juan Lacava Centro Oncología San Peregrino, Neuquén
Manuel Magallanes Hospital Militar, Colonia Roma, Delegación Cuauhtémoc

DOI:

https://doi.org/10.56969/oc.v17i4.125

Palabras clave:

cáncer de mama, uso temprano, América Central, América del Sur, quimioterapia, ixabepilona

Resumen

El uso racional del arsenal terapéutico actual permite a las mujeres con cáncer de mama mestastásico tener una supervivencia global mayor a la que tenían en la década de los ochenta. La racionalidad en la indicación (monoterapia secuencial vs. poliquimioterapia), las conductas pro-activas para el manejo de los eventos adversos, la aparición de terapias diana que benefician a grupos acotados de pacientes, el desarrollo de drogas quimioterápicas que vencen los mecanismos de resistencia habituales y logran respuestas interesantes (como las epotilonas) y el sostén y manejo de las metástasis óseas, les permite a las pacientes una mejor calidad de vida. En nuestra América Latina, con su particular realidad socio-económico-cultural y situación demográfica, la accesibilidad a los tratamientos en forma oportuna y equitativa y la instauración precoz de drogas útiles sigue siendo nuestro desafío cotidiano. En este artículo presentamos algunos casos clínicos que reflejan la práctica médica en tres países de la región.

Citas

O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 1: 20-9. DOI: https://doi.org/10.1634/theoncologist.10-90003-20

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Breast cancer. 2.2011. En: www.nccn.com; consultado el 9/11//2011.

Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011; 29: 2144-9. DOI: https://doi.org/10.1200/JCO.2010.31.5374

Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 20: 816-27. DOI: https://doi.org/10.1093/annonc/mdn728

Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004; 11: 82-5. DOI: https://doi.org/10.1007/BF02968008

Barbour SY. Caring for the treatment-experienced breast cancer patient: the pharmacist’s role. Am J Health-Syst Pharm 2008; 65: S16-22. DOI: https://doi.org/10.2146/ajhp080090

Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010; 12: S2. DOI: https://doi.org/10.1186/bcr2573

Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-92. DOI: https://doi.org/10.1002/path.1706

Giaccone G, Pinedo HM. Drug resistance. Oncologist 1996; 1: 82-7. DOI: https://doi.org/10.1634/theoncologist.1-1-82

Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 1991; 51: 5275-83.

Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-25. DOI: https://doi.org/10.1074/jbc.272.27.17118

Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2: 123-48. DOI: https://doi.org/10.2174/1568011023354489

Prospecto de ixabepilona (Ixempra®). Bristol-Myers Squibb Co., Princeton, Nueva Jersey.

Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-7. DOI: https://doi.org/10.1200/JCO.2007.12.6557

Jassem J, Fein L, Karwal M, et al. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast 2012; 21: 89-94. Epub 2011 Sep 21. DOI: https://doi.org/10.1016/j.breast.2011.09.003

Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407-14. DOI: https://doi.org/10.1200/JCO.2006.09.3849

Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recur- rence. Clin Cancer Res 2007; 13: 4429-34. DOI: https://doi.org/10.1158/1078-0432.CCR-06-3045

Verma S, Clemons M. First-line treatment options for patients with HER-2-negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncolo- gist 2007; 12: 785-97. DOI: https://doi.org/10.1634/theoncologist.12-7-785

Palmieri C, Krell J, James CR, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 2010; 7: 561-74. DOI: https://doi.org/10.1038/nrclinonc.2010.122

Geiger S, Cnossen JA, Horster S, DiGioia D, Heinemann V, Stemmler HJ. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005. Anticancer Drugs 2011; 22: 933-9. DOI: https://doi.org/10.1097/CAD.0b013e32834860af

Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncol 2008; 13: 214-21. DOI: https://doi.org/10.1634/theoncologist.2007-0167

OliveiraEX,MeloEC,PinheiroRS,NoronhaCP,Carvalho MS. Acesso à assistência oncológica: mapeamento dos fluxos origem-destino das internações e dos atendimentos ambulatoriais. O caso do câncer de mama. Cad Saude Publica 2011; 27: 317-26. DOI: https://doi.org/10.1590/S0102-311X2011000200013

Velásquez-De Charry LC, Carrasquilla G, Roca-Garavito S. Equidad en el acceso al tratamiento para el cáncer de mama en Colombia. Salud Pública Mex 2009; 51: 246-53. DOI: https://doi.org/10.1590/S0036-36342009000800015

Knaul FM, Nigenda G, Lozano R, Arreola-Omelas H, Langer A, Frenk J. Breast cancer in Mexico: a pressing priority. Reprod Health Matters 2008; 16: 113-23. DOI: https://doi.org/10.1016/S0968-8080(08)32414-8

Gottret P, Schieber G. Health Financing Revisited: A Practioner’s Guide. Washington, DC: World Bank Publishers; 2006. DOI: https://doi.org/10.1596/978-0-8213-6585-4